Company intelligence / Profile preview

Necura Pharmaceuticals AG

Ownership: Private
Development stage: Commercial

Overview

Necura Pharmaceuticals AG developed pentamycin, a small molecule antifungal drug approved for the treatment of vulvovaginitis. The company appears to have at least one product on the market but no further clinical pipeline information was identified in available sources[7].

Therapeutic areas: Women's Health
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

pentamycin

Commercial

Indications: Vaginitis

Beyond the preview

Go deeper on Necura Pharmaceuticals AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Necura Pharmaceuticals AG.

Explore the full profile